Article

Uncovering the Underlying Mechanisms of Tumor Growth

Discovery may help tumor suppression on a molecular level.

In a new study, researchers discovered that the p53 tumor suppressor protein is able to control gene expression by binding to both DNA and RNA.

The protein p53 is most well-known for its ability to bind to DNA and control gene expression at the level of transcription (protein synthesis). Mutations that stop the DNA binding activity are frequently found in human cancers.

Although researchers have known that p53 harbors RNA binding capacity, it has been vastly overshadowed by its DNA binding activity.

In a study published in Oncogene, researchers were able to demonstrate that p53 suppresses the synthesis of its negative regulator MDMX, through a direct interaction between p53 and the MDMX mRNA. Furthermore, a classic p53 mutation that prevents DNA binding activity was shown to have differentiated activity towards MDMX synthesis.

Study authors noted that RNA binding is not sufficient to suppress MDMX synthesis per se, and would require an additional trans-suppressor domain of p53.

“We found mutant p53 proteins that do not bind DNA instead have an effect towards mRNA translation,” said lead researcher Robin Fåhraeus. “It has been known that p53s can promote tumor growth but it is not clear what lies behind this activity and RNA binding offers one possibility.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards